Is lymph node dissection necessary for staging while undergoing nephrectomy in patients with renal cell carcinoma?

Autor: Demir T; Bezmialem Vakif University, School of Medicine Hospital, Department of Medical Oncology, Istanbul, Turkey., Aliyev A; Bezmialem Vakif University, School of Medicine Hospital, Department of Medical Oncology, Istanbul, Turkey. Electronic address: draltayaliyev@gmail.com., Beşiroğlu M; Bezmialem Vakif University, School of Medicine Hospital, Department of Medical Oncology, Istanbul, Turkey., Araz M; Necmettin Erbakan University, Meram School of Medicine Hospital, Department of Medical Oncology, Konya, Turkey., Köstek O; Trakya University School of Medicine Hospital, Department of Medical Oncology, Edirne, Turkey., Sakin A; Van Yüzünzü Yıl University Hospital, Department of Medical Oncology, Van, Turkey., Shbair ATM; Bezmialem Vakif University, School of Medicine Hospital, Department of Medical Oncology, Istanbul, Turkey., Çoban G; Bezmialem Vakif University, School of Medicine Hospital, Department of Pathology, Istanbul, Turkey., Ersöz C; Bezmialem Vakif University, School of Medicine Hospital, Department of Urology, Istanbul, Turkey., Şeker M; Bezmialem Vakif University, School of Medicine Hospital, Department of Medical Oncology, Istanbul, Turkey., Türk HM; Bezmialem Vakif University, School of Medicine Hospital, Department of Medical Oncology, Istanbul, Turkey.
Jazyk: angličtina
Zdroj: Current problems in cancer [Curr Probl Cancer] 2021 Feb; Vol. 45 (1), pp. 100619. Date of Electronic Publication: 2020 Aug 06.
DOI: 10.1016/j.currproblcancer.2020.100619
Abstrakt: Objective: The essential treatment for patients with renal cell carcinoma is nephrectomy. As no lymph node dissection (LND) could be performed in the majority of these patients, healthy staging could not be carried out. In this study, we investigated the impact of LND during nephrectomy on patient survival.
Methods: A total of 181 patients-58 (32%) were female and 123 (68%) were male-were included in the study. Median follow-up period was 48 months. The patients were separated into 4 groups according to their stage during diagnosis; group 1 (T1-3N0M0), group 2 (T1-3NXM0), group 3 (T1-3N1M0), and group 4 (T1-4N0/XM1). The disease-free survival of nonmetastatic patients and the overall survival of all groups were calculated.
Results: Mean age was 58.4 ± 12.0 years. Median survival for Group 1 could not be reached. Median survival was 89 months in Group 2, 50 months in Group 3, and 39 months in Group 4 (P <0.001). There was no statistically significant difference between the N1 and M1 groups (P = 0.297). For the NX patient group without LND, median survival was 89 months, which is worse than the N0 group and better than the N1 group (P = 0.002).
Conclusions: Our study presumes that the patients without LND are not staged sufficiently, NX patients have worse survival rates when compared with N0 patients, node-positive patients have poor survival rates as do the metastatic patients, and it should be defined as TNM stage4.
(Copyright © 2020. Published by Elsevier Inc.)
Databáze: MEDLINE
Externí odkaz: